Autologous mesenchymal stem cell transplantation    (DrugBank: -)

1 disease
告示番号疾患名(ページ内リンク)臨床試験数
13多発性硬化症/視神経脊髄炎3

13. 多発性硬化症/視神経脊髄炎 [臨床試験数:3,050,薬物数:2,147(DrugBank:348),標的遺伝子数:244,標的パスウェイ数:228
Searched query = "Multiple sclerosis/Neuromyelitis optica", "Multiple sclerosis", "Neuromyelitis optica", "MS", "NMOSD", "Devic disease", "Balo concentric sclerosis", "Baló concentric sclerosis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
3 / 3,050 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT01377870
(ClinicalTrials.gov)
December 201119/6/2011Evaluation of Autologous Mesenchymal Stem Cell Transplantation (Effects and Side Effects) in Multiple SclerosisEffect and Side Effect of Mesenchymal Stem Cell in Multiple SclerosisMultiple SclerosisBiological: intravenous injection of mesenchymal stem cells;Biological: injection of cell free mediaRoyan InstituteNULLCompleted18 Years55 YearsAll22Phase 1;Phase 2Iran, Islamic Republic of
2NCT00813969
(ClinicalTrials.gov)
March 201122/12/2008Autologous Mesenchymal Stem Cell (MSC) Transplantation in MSA Phase I Study to Assess the Feasibility, Safety, and Tolerability of Autologous Mesenchymal Stem Cell Transplantation in Patients With Relapsing Forms of Multiple SclerosisRelapsing-Remitting Multiple Sclerosis;Secondary Progressive Multiple Sclerosis;Progressive Relapsing Multiple SclerosisBiological: Autologous mesenchymal stem cell transplantationThe Cleveland ClinicUniversity Hospital Case Medical CenterCompleted18 Years55 YearsBoth24Phase 1United States
3NCT01228266
(ClinicalTrials.gov)
December 201025/10/2010Mesenchymal Stem Cell Transplantation in MSAutologous Mesenchymal Stem Cell Transplantation in Multiple Sclerosis: a Randomized, Double-blind, Crossover With Placebo Phase II StudyMultiple SclerosisBiological: autologous mesenchymal stem cellsAlbert SaizInstituto de Salud Carlos IIITerminated18 Years50 YearsBoth9Phase 2Spain